Orexo AB reported a deeper second-quarter net loss as sales lagged behind analyst estimates and costs increased. Revenue for the quarter amounted to SEK 3.50 million, below the consensus projection of SEK 5 million.
Per-share results, before and after dilution, were -SEK 2.92 for the quarter. The company recorded an operating loss (EBIT) of -SEK 103.30 million and an EBITDA loss of -SEK 95.10 million.
Revenue fell relative to the same quarter a year earlier. Management attributed higher operating expenditures to continued research and development activity alongside organizational adjustments following the divestment of Zubsolv in the United States.
During the quarter Orexo said it moved forward with development of its rescue medication candidates and reported growing external interest in its AmorphOX drug-delivery technology. The company is engaged in several partnering discussions relating to the AmorphOX platform.
Orexo provided timing for upcoming clinical and regulatory milestones. The company expects to initiate a pivotal trial for OX640 in the fourth quarter of 2026, with top-line results targeted for the first quarter of 2027. Management also plans to resubmit the New Drug Application for Izipry in the third quarter of 2026 and is anticipating potential Food and Drug Administration approval in the first quarter of 2027.
To support continued development and to address outstanding legal matters connected to the Department of Justice, Orexo said it is evaluating opportunities for additional financing. The company did not provide further detail on the size or structure of potential funding.
Context and implications
The quarter's results reflect a combination of lower top-line performance and elevated investment in R&D and reorganization post-divestment. While Orexo highlights program advancement and external interest in its AmorphOX platform, the firm also faces near-term financing and legal considerations that it says it is working to resolve.
Investors and stakeholders will likely watch the timing and outcomes of the planned OX640 pivotal trial and the Izipry NDA resubmission closely, as those milestones carry potential material implications for the company's future revenue trajectory.